Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00734370
Other study ID # KP-2008-518
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2008
Est. completion date January 2012

Study information

Verified date September 2018
Source VU University of Amsterdam
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Virtual Reality Exposure Therapy (VRET) is an effective treatment for anxiety disorders, particularly for specific phobias as fear of heights and fear of flying (e.g. Powers & Emmelkamp, 2008). Recent technological advances (e.g. more realistic avatars) make research into the efficacy of VRET for participants with elevated agoraphobic symptoms desirable. Therefore, the aim of the present research proposal is to investigate the comparative efficacy of:

1. enhanced VRET making use of the latest avatar technology with

2. exposure in vivo in agoraphobic participants

3. wait-list control.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date January 2012
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- A full diagnosis of panic disorder with agoraphobia according to the DSM-IV

- Between the ages of 18-65 years

- Sufficient fluency in Dutch to complete treatment and research protocol

Exclusion Criteria:

- Presence of medical condition, assessed by self-report questionnaires at the intake (i.e., pregnancy, seizure disorder, pacemaker)

- Current use of Beta-blockers

- Current use of tranquilizers (Benzodiazepines)

- Unstable psychotropic medication

- Substance dependence

- Psychosis

- Depression with suicidal ideation

- Posttraumatic Stress Disorder

- Dementia or other severe cognitive impairment

- Bipolar Disorder

- Borderline Personality Disorder

- Anti-social Personality Disorder

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Virtual Reality Exposure Therapy for agoraphobic participants
This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of Psycho-education, breathing training and cognitive restructuring Virtual reality Exposure to agoraphobic situations and interoceptive exposure Relapse prevention
Standard exposure in vivo for agoraphobic participants
This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of Psycho-education, breathing training and cognitive restructuring Standard exposure in vivo to agoraphobic situations and interoceptive exposure Relapse prevention (according to the protocol of Craske & Barlow)

Locations

Country Name City State
Netherlands University of Amsterdam Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
VU University of Amsterdam

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Panic Disorder Severity Scale (PDSS); Mobility Inventory for Agoraphobia (MI); Behavioural Avoidance Test (BAT) Assessed at pre- and post-treatment and 6-12 months follow-up
Secondary Beck Anxiety Inventory (BAI); Anxiety Sensitivity Inventory (ASI); Beck Depression Inventory (BDI); Panic Disorder Severity Scale (PDSS); Agoraphobic Cognitions Questionnaire (ACQ); Bodily Sensations Questionnaire (BSQ); Panic Appraisal Inventory (PAI) Process measures are taken prior to treatment, after the fourth treatment session and at post-treatment. The same measures will also be taken at 6 months follow-up. Process measures: are taken prior to treatment, after the fourth treatment session and at post-treatment. The PDSS and PAI will be administered every therapy session
See also
  Status Clinical Trial Phase
Recruiting NCT05868135 - Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Completed NCT02998502 - The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens N/A
Completed NCT01955954 - Using the Canary Breathing System for Panic Disorder Patients N/A
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT01201967 - A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Phase 4
Completed NCT00711737 - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00605813 - Special Investigation Of Long Term Use Of Sertraline.
Completed NCT00353470 - Comparison of Psychotherapy Programs to Treat Panic Disorder Phase 3
Completed NCT00167479 - A Study of Risperidone Monotherapy in Bipolar Anxiety Phase 4
Completed NCT00540098 - Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Phase 4
Completed NCT03233542 - The Association Between Physical Sensations and Thinking Styles N/A
Recruiting NCT05967468 - Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder N/A
Completed NCT02811458 - Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders N/A
Active, not recruiting NCT05124639 - Clinical Trial of a Group Self-management Support Program for Anxiety Disorders N/A
Completed NCT04592536 - A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects Phase 1
Completed NCT00025974 - Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder N/A
Recruiting NCT02305537 - Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment N/A
Terminated NCT01680107 - D-cycloserine Augmented CBT for Panic Disorder Phase 3